• Quotes
  • Shortcuts
The Executive's Internet
Tues, July 14th
editor corner icon Editor's Corner | Archive
How to Make Your Brand More Cohesive: Learn tips for early business growth and branding. Patricia
icon
GoogleAmazonWikipedia
site of the day icon Site of the Day | Archive
Broadcastify
The world's largest source of public safety, aircraft, rail, and marine radio live audio streams


spacerspacer

 

 BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'stock'. (Return)

Forbes HeadlinesJul 14, 2020
Best Stocks To Buy As Markets Rally Despite Elevated Volatility
Despite setting an intraday record yesterday, Nasdaq ended the day with a sharp reversal. More choppiness should be expected as more companies declare their quarterly results throughout the week. Using our AI, we have the Top Buys for today.

RELATED ARTICLES
Best Companies To Short As Nasdaq And Tech Stocks Retreat (Forbes Headlines)

NYTimes BusinessJul 14, 2020
Stocks Unsteady as Earnings Season Begins: Live Updates


RELATED ARTICLES
Stocks steady as banks kick off earnings season (USA Today Money)

The Motley FoolJul 14, 2020
Stock Markets Open Mixed Tuesday as Big Banks, Delta Earnings Weigh
Solid results weren't enough to pull some stocks out of their recent dives.

Yahoo BusinessJul 14, 2020
IMV Pops 134% In Pre-Market On "Rapid Progress" Of Covid-19 Vaccine Development
Shares in IMV Inc. (IMV) are spiking 134% in Tuesday's pre-market trading after the clinical-stage biopharma company said it made "rapid progress" in developing its candidate vaccine to prevent COVID-19 infection.The stock surged to $4 in pre-market trading as IMV said that it was working closely with regulatory agencies and its partners to initiate clinical studies as quickly as possible. The plan for the Phase 1 clinical study, agreed with Health Canada, is a randomized controlled study, assessing the safety and immunogenicity of its vaccine candidate DPX-COVID-19, to be conducted in 84 healthy adults across two age cohorts.DPX-COVID-19, is based on the Canadian biotech's first-in-class lipid-based vaccine delivery platform that generates targeted and sustained immune response in vivo. Fully synthetic, the vaccine candidate is designed to focus the immune response on the weaknesses of the virus with the goal to optimize safety and efficacy."The rapid progress in target selection, the vaccine formulation, manufacturing and preclinical results so far not only demonstrate the potential of our delivery platform, but also build on our previously reported clinical data from a similarly designed vaccine against RSV, the respiratory syncytial virus," says IMV CEO Frederic Ors. "Clinical results have shown our DPX-based vaccine against RSV demonstrated a unique ability to generate safe and long-lasting immune responses in older adults."IMV, a pioneer in a novel class of cancer immunot

MarketWatch MarketPulseJul 14, 2020
Bed Bath and Beyond sees 'positive' same-store sales, cash flow in June
Shares of Bed Bath & Beyond Inc. rose 1.1% in premarket trading Tuesday, after the home accessories retailer said June same-store sales were "positive" for reopened stores and digital channels. The company said cash flow during June were also positive. Nearly all stores have reopened, following closures because of the COVID-19 pandemic. Separately, the company said it believes there is between $350 million to $450 million it could get from asset sales and the plan to reduce up to $1 billion of inventory at retail is slightly more than halfway complete. The stock has run up 43.9% over the past three months through Monday, while the SPDR S&P Retail ETF has advanced 25.3% and the S&P 500 has gained 10.9%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



MarketWatchJul 14, 2020
There's a bearish pattern in the stock market, but momentum investors are hanging tough
Buyers of momentum stocks have made a lot of money, so they're unlikely to give up soon.

RELATED ARTICLES
NewsWatch: This strategist says investors are in the ‘forest of make believe' when it comes to growth stocks (MarketWatch)
Need to Know: This strategist says investors are in the ‘forest of make believe' when it comes to growth stocks (MarketWatch)

Yahoo BusinessJul 14, 2020
Equillium (EQ) Stock Price Target Gets a Big Boost; Here's What You Need to Know
Headline grabbing biotechs are far from a rare sight in 2020. Nevertheless, when a little-known micro-cap pops by 730% in a single trading session, avid market followers are likely to take notice.And so to Equillium (EQ), the aforementioned little known biotech, whose shares blasted off on Monday.The rally began following the announcement that the Drugs Controller General of India - India's equivalent of the FDA - granted Equillium's partner Biocon emergency approval for itolizumab, a treatment of cytokine release syndrome (CRS) in COVID-19 patients with acute respiratory distress syndrome (ARDS). The approval came following a 30-patient proof-of-concept trial in which the drug reduced mortality in hospitalized COVID-19 patients (all patients given the drug survived).The drug is currently being developed as a treatment for various autoimmune and inflammatory diseases. However, Equillium now plans to file an investigational new drug (IND) application so it can proceed with a clinical trial of itolizumab in COVID-19 patients in the US.H.C. Wainwright analyst Ram Selvaraju believes progress could be fast once the wheels are set in motion."In our view," said the 5-star analyst, "itolizumab could be developed rapidly using a similar trial design in a larger patient group—perhaps no more than 200-400 subjects—with a randomized, double-blinded, controlled approach. Such a trial program in the U.S. could be accomplished involving only 10-12 centers and might cost under $10M to exec

CNBC FinanceJul 14, 2020
Dow rises 200 points as JPMorgan climbs on earnings, but gains capped as Big Tech struggles again
Stocks opened lower on Tuesday as shares of major tech companies added to their late-day reversal from the previous session.

Forbes HeadlinesJul 14, 2020
Trading Revenue Jumps But JPMorgan, Wells Fargo And Citigroup See More Losses In Second Quarter
Big banks are still stockpiling cash to prepare for a wave of loan defaults as the coronavirus crisis wears on.

MarketWatchJul 14, 2020
Market Snapshot: Dow up 250 points at midday Tuesday, Nasdaq down after briefly flipping positive
U.S. stock-indexes are mixed at midday Tuesday in volatile trading as investors monitor technology stocks and digested second-quarter earnings results from a trio of big banks.

Google Business NewsJul 14, 2020
Is Moderna Stock A Buy As It Leads The Coronavirus Vaccine Race? - Investor's Business Daily
Is Moderna Stock A Buy As It Leads The Coronavirus Vaccine Race?  Investor's Business DailyModerna Analyst: Coronavirus Vaccine Will Get Approved, Clock $5B In Orders Over Next Few Years  Yahoo! VoicesRussia Coronavirus Vaccine Could Be Distributed Next Month  NewsweekPolitics endanger COVID-19 vaccine  The Boston GlobeRussia's first vaccine against COVID-19 | Sechenov University  WION

The Motley FoolJul 14, 2020
Forget Apple, IBM Is a Better Dividend Stock
Big Blue's shareholder-friendly dividend policy leaves Cupertino in the dust.

MarketWatch MarketPulseJul 14, 2020
Tesla stock surges after Piper Sandler boosts price target above $2300
Shares of Tesla Inc. are up more than 4% in premarket trading Tuesday after Piper Sandler analyst Alexander Potter raised his price target on the stock to $2322 from $939, writing of "faster-than-expected share gains" and big opportunities in software. Though Tesla shares have rocketed nearly 260% on the year and the stock's valuation is 88 times higher than it was after its 2010 initial public offering, Potter said that "resoundingly" his conclusion is to stick with the stock. "While deliveries are a key driver of our increased near-term estimates, software is the biggest driver of our increased DCF-based price target," he wrote in a late Monday note to clients. "Tesla has noted the possibility for 30% gross margins if/when more customers opt-in for purchasing the company's full self-driving (FSD) software." That could help Tesla record operating margins in the "mid-20s" by the end of Potter's 20-year forecast period, even if only half of customers go for the full self-driving software. "Thanks to the high-margin nature of the FSD package, we think that by the 2030s, Tesla could conceivably be selling vehicles at cost - or even below cost - while still achieving higher operating margins," he wrote. Tesla shares have surged 60% in the past month alone as the S&P 500 has added about 4%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



FT.com - Financial MarketsJul 14, 2020
Offshore investors dump China stocks after ‘incredible' rally
Funds outside the mainland sell a record $2.6bn of Chinese stocks in a day

Yahoo BusinessJul 14, 2020
Making sense of Tesla's parabolic rally: Morning Brief
Top news and what to watch in the markets on Tuesday, July 14, 2020.


CNBC FinanceJul 13, 2020
Stocks making the biggest moves after hours: Tesla, BioNTech, Moderna and more
See which stocks are posting big moves after the bell.
TRENDING TAGS
Coronaviruscases vaccine latest updates record
pandemicCoronavirus How during travel Last
StockEarnings market Buy Tesla rise
StocksEarnings investors Season making biggest
Chinasanctions Lockheed Taiwan South Sea
EarningsSeason Stock Stocks futures rise
HuaweiUK 5G ban Bans Networks
fundFiler Hedge Right INC shares
billionloss Wells Fargo dividend cents
COVID-19cases Vaccine Company states Jakarta

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC